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Glioblastoma are notorious for their highly invasive growth, diffusely infiltrating adjacent brain structures that precludes com-
plete resection, and is a major obstacle for cure. To characterize this “invisible” tumor part, we designed a high resolution
multimodal imaging approach assessing in vivo the metabolism of invasively growing glioma xenografts in the mouse brain.
Animals were subjected longitudinally to magnetic resonance imaging (MRI) and 1H spectroscopy (MRS) at ultra high field
(14.1 Tesla) that allowed the measurement of 16 metabolic biomarkers to characterize the metabolic profiles. As expected,
the neuronal functionality was progressively compromised as indicated by decreasing N-acetyl aspartate, glutamate and
gamma-aminobutyric acid and reduced neuronal TCA cycle (258%) and neurotransmission (250%). The dynamic metabolic
changes observed, captured differences in invasive growth that was modulated by re-expression of the tumor suppressor gene
WNT inhibitory factor 1 (WIF1) in the orthotopic xenografts that attenuates invasion. At late stage mice were subjected to 13C
MRS with infusion of [1,6-13C]glucose and 18FDG positron emission tomography (PET) to quantify cell-specific metabolic fluxes
involved in glucose metabolism. Most interestingly, this provided the first in vivo evidence for significant glucose oxidation in
glioma cells. This suggests that the infiltrative front of glioma does not undergo the glycolytic switch per se, but that environ-
mental triggers may induce metabolic reprograming of tumor cells.
Introduction
Glioblastoma (GBM) are difﬁcult to treat. The functional
plasticity of glioma stem-like cells, the heterogeneity within
glioma cell populations, along with their high migratory
potential are main obstacles toward an effective treatment.
Little is known on the metabolism of the invasive tumor
front. While mostly invisible to magnetic resonance imaging
(MRI), it lies outside the resected and irradiated area, and is
highly relevant for tumor recurrence. The latter has been fur-
ther emphasized in a recent cell tracing model, demonstrating
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a large overlap between cell clones in the invading front and
tumor sustaining clones after serial orthotopic transplantation
of human GBM cells in mice.1 Invading cells usually grow at
low cell density, surviving in a speciﬁc micro-environment
with an intact blood–brain barrier and availability of oxygen
and nutrients, suggesting that these tumor cells require dis-
tinct treatments. The characterization of the metabolic modi-
ﬁcations associated with the invasive phenotype may help to
target metabolic pathways relevant for invading cells.
The determination of the altered metabolic proﬁles in
GBM can be achieved in vivo in xenograft models using 1H,
13C magnetic resonance spectroscopy (MRS) and 18FDG pos-
itron emission tomography (18FDG PET).2,3 The determina-
tion of neurochemical proﬁles with 1H MRS in vivo at
ultrahigh magnetic ﬁeld (i.e., 14.1 T) using short echo-time
sequences allows the simultaneous detection of a large num-
ber of metabolites that otherwise display highly superimposed
signals, such as glutamate and glutamine, phosphocholine
and glycerophosphocholine, creatine and phosphocreatine,
myo-inositol and glycine.4,5 The metabolites that become
detectable provide insights into energy metabolism, myelina-
tion, neurotransmission, antioxidation and osmoregulation,
as recently reported from rodent xenograft models of
glioma.6,7
The combination of 18FDG PET and 13C MRS in vivo
allows the assessment of glucose metabolism through aerobic
and anaerobic pathways. While PET measures total glucose
consumption without distinguishing between different meta-
bolic pathways subsequent to glucose phosphorylation, 13C
MRS assesses during the infusion of 13C-labeled glucose the
incorporation of the stable isotope 13C into metabolites
downstream of glycolysis, such as glutamate and glutamine.
This aspect is of particular interest in the current debate on
cancer metabolism and mitochondria as recent ex vivo stud-
ies have provided for the ﬁrst time evidence for active glu-
cose oxidation in human GBM cells,8,9 while standard
teaching on tumor cell metabolism decrees that tumor cells
would preferentially metabolize glucose to lactate, the so-
called Warburg effect.
Therefore, the overall aim of the present longitudinal
study was to identify the temporal metabolic modiﬁcations in
a highly inﬁltrating and non-necrotic mouse glioma xenograft
model, whose invasive properties and outcome were modu-
lated by expression of the tumor suppressor gene WNT
inhibitory factor 1 (WIF1).10 The use of an in vivo multi-
modal imaging approach with 1H MRS and MRI at ultrahigh
magnetic ﬁeld (14.1 T) and short echo-time allowed longitu-
dinal measures of 16 brain metabolites to characterize tumor
inﬁltration. Late stage metabolism was examined with 18FDG
PET and 13C MRS upon infusion of [1,6-13C]glucose, and
subjected to compartmentalized metabolic ﬂux analysis to
elucidate metabolic fates of glucose in GBM cells.
Methods
Orthotopic mouse glioma model
GBM sphere cells LN-2669GS (105 cells) transduced with
either the WIF1 expression vector (LN-2669GS_WIF1) or the
empty vector control (LN-2669GS_pIRES2) were stereotaxi-
cally injected into the caudoputamen of male Swiss nu/nu
mice as previously described.10 The use of male mice avoids
potential effects of the oestrous cycle on the metabolism. The
parental GBM sphere line LN-2669GS has been established
and maintained in our laboratory under stem cell conditions
as described previously,11 and has been molecularly charac-
terized (TP53 wild-type, PTEN mutant, NF1 mutant,
CDKN2A homozygous deletion; GEO accession numbers
GSE60274, GSE108098 and GSE104291 for DNA methyla-
tion, aCGH and gene expression data, respectively), and
authenticated by DNA ﬁngerprinting.11–13 The mice entered
into our study correspond to a subset of a larger cohort (15/
20) demonstrating a tumor suppressing effect of WIF1 as
reported previously.10 Experimental and molecular descrip-
tion of the model in vitro and in vivo is available in Vassallo
et al.10 Mice exhibiting tumor growth between the dura and
the skull were excluded (3/15) to avoid potential artifacts, as
the tumor mass compresses the underlying brain leading to
gliosis. All animal experiments were approved by the veteri-
nary authorities (VD1181.3-6).
In vivo
1H magnetic resonance spectroscopy
All MRI/MRS experiments were carried out in a 14.1 Tesla
28-cm horizontal bore animal scanner (Agilent Technologies,
Palo Alto, CA). In vivo 1H MRS was performed with a short
echo-time (TE5 2.8 ms) spin echo full-intensity sequence.4
Quantitative 1H MRS data were obtained as absolute concen-
trations (in micromole/g) using water as internal reference.3,14
The experimental and technical details are described in the
Supporting Information methods.
What’s new?
Glioblastomas are diffusely infiltrative tumors with an invasive margin that frequently lies beyond resected and irradiated
areas of the brain. It is suspected that invasive glioma cells sustain diffusely infiltrative growth in microenvironments with an
intact blood barrier via unique metabolic modifications. Here, using 1H-Magnetic resonance spectroscopy (MRS) at ultra-high
magnetic field, 16 metabolites were monitored during invasive growth of patient-derived glioblastoma xenografts in the mouse
brain. In vivo cell-specific flux analysis by 18FDG-PET and 13C-MRS revealed significant glucose oxidation of invasively growing
glioma cells, challenging the Warburg effect, according to which cancer cells rely primarily on glycolytic metabolism.
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In vivo
18FDG positron emission tomography
Injected mice were scanned with 18FDG PET at presentation
of ﬁrst neurological symptoms, and left to recover for 24–36
hr before the 13C labeling experiment. Age-matched control
mice were scanned under identical conditions. All experimen-
tal procedures were carried out with an avalanche photodiode
micro-PET scanner (LabPET4, Gamma Medica, Sherbrooke,
Canada). A bolus of 18FDG was administered through the tail
catheter during the ﬁrst 10 sec of the scan (1.46 0.2 MBq/g;
mean6 SD), followed by a saline chase (100–150 mL). The
total duration of the scan was 50 min to reach a steady-state
in 18FDG kinetics to determine the FDG standardized uptake
value. See Supporting Information methods for details.
In vivo
13C magnetic resonance spectroscopy and
metabolic flux analysis
In brief, mice were fasted for 7 hr with free access to water
before experiments, to deplete endogenous glucose. In vivo
1H MRS was performed on the volume of interest (112 mL,
3.7 mm 3 6.9 mm 3 4.5 mm covering the striatum in both
hemispheres, or 60 mL, 3.6 mm 3 3.7 mm 3 4.5 mm) to
quantify the neurochemical proﬁle in the region and to quan-
tify glutamate (Glu) and glutamine (Gln) pool size. Total
metabolite concentrations are assumed to remain constant
throughout the scan. Glycemia was measured before labeled
glucose injection. A 5 min bolus injection was followed by 4
hr of continuous infusion of [1,6-13C]glucose to reach steady-
state labeling conditions in plasma glucose (70% fractional
enrichment). The acquired dynamic 13C MRS spectra were
scaled to absolute concentrations using the 13C multiplet pat-
terns of the glutamate resonances and the total glutamate
pool size, enabling a fully quantitative determination of the
metabolic ﬂuxes. The standardized infusion protocol and the
detection techniques are detailed in the Supporting Informa-
tion methods.
Individual time courses of 13C labeling for glutamate and
glutamine C4, C3 and C2 were integrated into a modiﬁed
two-compartment model for brain metabolism in which one
compartment is assigned to neurons, while the other is
shared between glial and GBM cells, based on the hypothesis
that the glucose metabolism in GBM cells is structurally simi-
lar to glial cells. This model assumes that GBM cells actively
oxidize glucose and acetate, as previously shown in ex vivo
models.8,15 Glutamine is mainly oxidized from glucose and
catabolism of blood-born glutamine is not found to be signif-
icant in such cells.8 A more detailed description of the model
assumptions and differential equations is described else-
where16 and Supporting Information methods.
Quantification of human glioma and mouse cells
Coronal brain sections in the plane of the injection were
immunostained for human nucleolin (hNCL) as described, to
identify the human glioma cells.10 Human glioma cells and
mouse cells were quantiﬁed in a square of 0.5 mm2, placed at
the location evaluated for metabolite concentrations by 1H
MRS (Fig. 1).
Statistical analyses
The concentrations of the metabolites were examined by
principal component analysis (PCA). A Monte-Carlo Test
(999 permutations; global test) was performed to test over-
all difference between groups.17 The missing values were
imputed by regularized iterative PCA algorithm.18 All anal-
yses and graphical representations were performed in R
(URL http://www.R-project.org) and the R packages mis-
sMDA and ade4.19,20 Statistical signiﬁcance of metabolite
concentrations between groups and between maximum/
minimum values at each time point and initial values were
evaluated with Student’s t-test. Linear correlations were
tested by determining R2, the slope and the p-values for
the null hypothesis (zero slope of the regression line) for
each group. p-Values  0:05 were considered statistically
signiﬁcant.
Results
To assess the temporal changes of metabolic proﬁles captur-
ing the evolution of tumor growth, in vivo 1H MR images
and spectra were acquired longitudinally at 14.1 Tesla of a
highly invasive orthotopic glioma model (Fig. 1). Tumor
bearing mice followed and analyzed in our study were part of
a larger cohort (12/20) of a project investigating the mecha-
nistic effects of re-expression of the tumor suppressor gene
WIF1 on invasion and migration in vivo and in vitro as
reported previously.10 First scans were performed 6 weeks
after injection of the mice and repeated every week, as illus-
trated for all mice in Supporting Information Figure S1
(n5 8, injected with the GBM-derived sphere-line LN-
2669GS_WIF1; n5 4, injected with vector control LN-
2669GS_pIRES2; n5 7, non-injected age-matched control
mice). T2-weighted images were devoid of focal tumors, and
tumor progression was not visible on MR images. However,
the injected side of the striatum appeared expanded,
inﬂuencing the ventricle size (Fig. 1a). At ﬁnal sacriﬁce,
visualization of the human cells by immunohistochemistry
revealed diffuse distribution of the glioma cells in both
hemispheres (Fig. 1b) with a human/mouse cell ratio
between 0.3 and 1.8. However, there was one exception: in
mouse NCH-1444 the tumor was visible on MRI and
human cells were mainly restricted to the injected side with
a higher cell density (ratio human/mouse 2.6), and exhibit-
ing a diffuse growth pattern (Fig. 1b). Due to the distinct
behavior, NCH-1444 was treated separately in the following
analyses (green in the graphics).
1H MRS at ultrahigh magnetic ﬁeld (14.1 Tesla) and short
echo time provided excellent sensitivity (SNR5 16–27 in
8 mL) and spectral resolution allowing quantiﬁcation of 16
distinct metabolites simultaneously, such as glycine (Gly) and
myo-inositol (Ins), creatine (Cr) and phosphocreatine (PCr),
glycerophosphocholine (GPC) and phosphocholine (PCho)
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Figure 1. 1H Magnetic resonance spectroscopy and PET of orthotopic glioma xenografts. (a) 1H MRS spectra obtained at 14.1 Tesla from a
localized volume of 2 mm 3 2 mm 3 2 mm in the right striatum of a non-injected mouse, a mouse injected with LN-2669GS_pIRES2 cells
(14 weeks after injection, NCH-1423) and two mice injected with LN-2669GS_WIF1 cells (NCH-1428, 17 weeks; NCH-1444, 16 weeks). Cor-
responding axial slices of T2-weighted images and 18FDG PET are shown on the right (SUV, standard uptake values). In NCH-1444 the tumor
was mostly confined to the injected side. The MRI images correspond to the images shown in Figure 5, since they were taken before 1H
and 13C MRS during the same scanning session for each animal. (b) The respective tumor-bearing mouse brains (NCH-1423, NCH-1428) are
shown, stained for hematoxylin and eosin (H&E), and anti-human Nucleolin (hNCL) that detects human cells visualizing the highly invasive
properties in the injected and the contra-lateral side. NCH-1444 is an exception in the series. The distribution of the human tumor cells
indicates an invasive tumor that is basically confined to the injected side (human/mouse cells52.6) compared to only few tumor cells on
the contralateral side. [Color figure can be viewed at wileyonlinelibrary.com]
(Figs. 1 and 2). Metabolite concentrations and proﬁles deter-
mined longitudinally in non-injected mice were similar to
previous studies.21 The temporal evolution of the metabolite
concentrations averaged for each group at every time point is
reported in Figure 2a. The ﬁrst signs of tumor development
appeared at Week 7 after injection and manifested as a statis-
tically signiﬁcant increase in PCho and Ins, followed by a
reduction in N-acetyl aspartate (NAA) (Fig. 2a). Gly
Figure 2. 1H MRS data acquired during tumor development. (a) Longitudinal measurements of brain metabolites between Week 6 and Week
17 post injection. Non-injected mice (black), mice injected with LN-2669GS_pIRES2 (blue) and LN-2669GS_WIF1 (red), respectively. Mouse
NCH-1444 (LN-2669GS_WIF1) is an outlier, shown separately in green. Results are presented as averages6SD (mmol/g). Black asterisks
indicate a significant difference (p<0.05) for both groups while blue or red asterisks show significant differences for the pIRES2 and WIF1
group, respectively. (b) Correlations between the concentration of NAA, a highly specific neuronal marker, and the neurotransmitters gluta-
mate, GABA and glycine. Points represent measured concentrations in a single mouse at a single time point expressed in mmol/g. The lin-
ear fit curve and the respective statistics are shown for the pIRES2 and WIF1 group, and for NCH-1444, separately.
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increased after Week 11. NAA decreased steadily, reaching a
plateau for long-term surviving mice (5 mmol/g at 18–20
weeks). The same fate was shared by the main neurotrans-
mitters Glu and GABA. PCho reached a maximum increase
between 16 and 18 weeks and tapered off thereafter. In con-
trast, GPC, and Gly showed a signiﬁcant linear increase and
alanine (Ala) a signiﬁcant decrease until ﬁnal sacriﬁce. All
other metabolites only showed increased variability over time,
without a clear evolution pattern. NCH-1444 behaved as an
outlier that may reﬂect the distinct growth pattern. Signiﬁ-
cant positive linear correlations were observed between con-
centrations of NAA and the neurotransmitters Glu, and
gamma-aminobutyric acid (GABA), and a signiﬁcant negative
correlation with Gly (Fig. 2b).
The metabolic proﬁles obtained by MRS for all mice over
time were analyzed by PCA (Fig. 3a). The main structure of the
data was explained by the ﬁrst axis (40.5% of inertia) mostly
characterized by metabolites linked to neuronal metabolism
(NAA, Glu and GABA) that are negatively correlated with
markers speciﬁc for high cellular turnover such as choline com-
pounds. Gly, Gln and Ins resulted in relevant projection on the
same axis, although shorter than NAA, Glu and GABA. No dif-
ference was observed between the two different tumor groups
(WIF1 vs. empty vector; p-values5 0.09) when time was not
considered (Fig. 3a). The non-injected mice (projected, but not
active in the PCA) were homogeneous, characterized by elevated
concentration of NAA, Glu and GABA.
A gradual change of the PCA values was observed over time
associated with diffuse tumor growth (Fig. 3b) as reﬂected by
modiﬁed metabolic proﬁles measured by the means of 1H MRS
(Figs. 1a and 2a). At early time points, both the controls and
the injected mice are located in the same region deﬁned by
neuron-related metabolites. Injected mice shifted over time to
the region characterized by metabolite markers for high cell
turnover (choline compounds), while the metabolite proﬁles of
the non-injected mice did not change (Fig. 3b). The lowess
curve for WIF1 expressing xenografts is shifted towards later
time points as compared to the vector control, although it did
not reach signiﬁcance. The trend toward later time points is in
agreement with a tumor suppressing effect of WIF1 that pro-
longs survival of the mice as determined in the complete mouse
cohort (see Methods)10 and other orthotopic glioma xenograft
models.10,22 NCH-1444 showed a more pronounced evolution
over time, in line with the distinct metabolic features described
above (Figs. 2a and 2b).
Last time point analysis: association between metabolites
and tumor burden
When tumor bearing mice presented ﬁrst neurologic symp-
toms a last 1H MRS scan was performed before sacriﬁce. The
metabolic proﬁles linked to the symptomatic tumor-stage
typically featured signiﬁcantly increased concentrations of
total choline (tCho, GPC1 PCho), lower NAA, Glu and
GABA, and higher Gln and Ins (Figs. 1a and 2a). Of note,
no elevated lactate levels were observed. Similar to the
longitudinal analysis, the ﬁrst axes of the PCA (39.6% of
inertia) of the end stage proﬁles was dominated by NAA,
GABA and Glu, in anti-correlation with tCho (Fig. 4a).
PCho projection on the ﬁrst axis is close to zero, while GPC
is mostly aligned with tCho (Fig. 4a), reﬂecting a more
important contribution of GPC to tCho increase at late stage
compared to PCho. Taurine (Tau) and macromolecules
(Mac) have a long projection on the same axis strongly cor-
related with NAA. The second axis (20% of inertia) is related
to Ala, lactate (Lac), Gln and Ins. The tumor density was
classiﬁed into LOW and HIGH (ratio human/mouse cells 1
vs. >1), visualized by the ellipses in Figure 4a. The difference
between the groups did not reach signiﬁcance on the ﬁrst
axis of the PCA (p-values5 0.18, Fig. 4b). However, using
continuous values, the coordinates of the mice on the ﬁrst
axis were signiﬁcantly correlated with their tumor cell ratio
(Fig. 4c, Spearman correlation, r5 0.682, p-values5 0.025).
HIGH density tumors were characterized by markers of
membrane turnover (choline compounds), while the LOW
density tumors were associated with healthy neuronal metab-
olism (NAA, Glu, GABA and Tau).
Signiﬁcant linear relationships between individual metabo-
lites and the ratio human/mouse cells were found for NAA,
Glu, Gly, GPC and Mac (Fig. 4d), but not PCho, Ins and
Gln, that were, however, measured at higher concentrations
compared to non-injected mice. The remaining metabolites
were uncorrelated with the increasing relative number of gli-
oma cells. Of note, no difference was found between the
mice injected with WIF1 cells or the vector control at the
time of sacriﬁce (Supporting Information Fig. S2). This was
in agreement with the overall analyses when ignoring time
(Fig. 2a) and was expected given that all mice were symp-
tomatic at the time of sacriﬁce.
To assess glucose metabolism 18FDG PET acquisitions
were performed after the last 1H MRS scan, which did not
show increased standardized uptake values (SUV) for glucose
in the volume of interest examined during 1H MRS scans
(SUVinject5 1.46 0.4 g/mL; 8 mL, right striatum) compared
to the contralateral side (SUVcontra5 1.36 0.2 g/mL, left stri-
atum). Comparable SUV values were found in the left stria-
tum of non-injected mice (1.76 0.3 g/mL). Therefore,
glucose uptake was not found to increase locally in presence
of GBM cells at late stage (Fig. 1a).
Brain energy metabolism was measured by 13C MRS in 6
glioma-bearing mice by infusing [1,6-13C]glucose as a last
experiment. For subsequent metabolic ﬂux analysis, fractional
enrichment (FE) curves were averaged over 3 mice with simi-
lar metabolite proﬁles and human/mouse cell ratio (1.7–1.8,
Fig. 4; Supporting Information Figs. S3 and S4). Spectra from
NCH-1444 are shown separately in Figure 5c as an extreme
case of a cell dense tumor environment (human/mouse cell
ratio5 2.6). 13C MRS spectra were acquired in vivo over 4
hr. Results collected in glioma bearing mice were compared
to data from similar labeling experiments performed on 6
non-injected mice.16 The glutamate pool was signiﬁcantly
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reduced in the tumor bearing group (p< 0.0001), while gluta-
mine appeared more concentrated compared to non-injected
mice (p< 0.05) (Supporting Information Fig. S3).
In vivo spectra exhibited fully resolved resonances for the
C4, C3 and C2 of Glu and Gln (Figs. 5a and 5b). Moreover,
spectra acquired from only 60 mL VOI in 64 min at steady-
state still featured a very good SNR (6) and spectral resolu-
tion (25 Hz) (Fig. 5c). Comparison between steady-state
spectra acquired for 64 min after 3 hr of infusion showed a
distinct labeling pattern in glioma bearing brains (Figs. 5b
Figure 3. Longitudinal metabolite profiles. (a) Biplot of the PCA of the longitudinal metabolite profiles. Each scan is indicated by a dot
(black, control, non-injected mice; red, mice injected with LN-2669GS_WIF1 cells; blue, mice injected with LN-2669GS_pIRES2 cells; green,
NCH-1444). The inertia ellipses visualize the mice corresponding to the three groups. The non-injected mice and NCH-1444 are visualized,
but not active in the analysis. (b) Scatter plot of the mouse coordinates on the first axis plotted against time from injection (weeks). A non-
parametric regression line (lowess) is added for each group to show the tendencies over time. The corresponding one-dimensional repre-
sentation of the metabolite coordinates for the first axis of the PCA is shown on the right. GSH, glutathione; Mac, macromolecules.
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Figure 4. Metabolite profiles at the last time point and tumor cell ratio. (a) The metabolite profiles of all xenografts at the last time point
are presented in a PCA showing the two first axes. (b) The ratio of tumor over host cells was used to classify the mice into HIGH and LOW,
using 1 as threshold, visualized by red stars and blue circles, and corresponding inertia ellipse (p-values50.186); NCH-1444 (green
square) is inactive in the analysis. (c) The correlation between the 1st axes of the metabolite profile and the density of the tumor cells
(ratio human/mouse cells) is significant (rho5 0.682, p-values50.025). (d) Linear regressions established between brain metabolite con-
centrations at the last scan and the human/mouse cell ratio (only metabolites with significant correlation). Symbols represent single mouse
measurements (mmol/g). The experimental point shown as “null content” for GBM cells represents the average metabolite concentration in
non-injected mice of the same brain region (group mean6SD). The outlier NCH-1444 (green square) is not included in the linear regres-
sion. Significant correlations are indicated (*p<0.05, **p<0.01, Student’s t-test). [Color figure can be viewed at wileyonlinelibrary.com]
Figure 5. In vivo 13C MR spectra acquired at steady-state of [1,6-13C]glucose infusion of a control and tumor bearing brains.
13C MR spectra were acquired after 3 hr of [1,6-13C]glucose infusion during 64 min. The volume was 112 mL (3.6 mm 3 6.9 mm 3
4.5 mm) covering the central brain on both hemispheres for the non-injected mouse brain (a) and the brain with the invasively
growing tumor NCH-1423 (b). NCH-1444, acquired in a 60 mL voxel (3.6 mm 3 3.7 mm 3 4.5mm) centered in the injected side
(c). MRI images are the same as shown in Figure 1a, since they were taken before 1 H and 13C MRS during the same scanning session
for each animal. [Color figure can be viewed at wileyonlinelibrary.com]
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and 5c) as compared to non-injected brains (Fig. 5a). Accu-
mulation of labeling in Glu was reduced in all three carbon
positions, while the absolute concentration in Gln-labeled
carbons appeared higher as compared to control mice (Fig.
5a). Labeling of LacC3 from glycolysis did not appear
increased in the tumor bearing brains (Figs. 5b and 5c).
Distinct time courses of Glu and Gln C4, C3 and C2
(Supporting Information Fig. S4) were ﬁtted to a two-
compartmental model for energy metabolism adapted for
glioma-bearing mice (Fig. 6a), yielding a rate of the neuronal
TCA cycle (VnTCA5 0.226 0.02 mmol/g/min) and the TCA
cycle rate accounting simultaneously for glial and glioma cells
(Vg5 0.306 0.06 mmol/g/min), pyruvate carboxylase activity
in the glial-GBM compartment (VPC5 0.0596 0.007 mmol/g/
min), and the neurotransmission rate (VNT5 0.056 0.02
mmol/g/min). The glial-GBM compartment showed signiﬁ-
cant glucose oxidation through TCA cycle (Vg) and anaplero-
sis (VPC), while the estimated values of neuronal TCA cycle
(VnTCA) and neurotransmission (VNT) were signiﬁcantly lower
in glioma bearing mice (p< 0.5 and 0.001 respectively) com-
pared to healthy animals (respectively 258% and 250%) as
visualized in Figure 6b (Supporting Information Table S1).
Discussion
Our study characterizes for the ﬁrst time in vivo longitudinal
metabolite proﬁles of an orthotopic glioma sphere line model
with highly inﬁltrative behavior, thereby providing information
on the metabolic changes during invasive growth in absence of
tumor necrosis. The metabolite proﬁles allowed the association
between tumor burden and the modiﬁcation of metabolite con-
centrations. Moreover, compartmentalized modeling of dynamic
13C MRS data allowed the distinction of neuronal metabolism
from metabolism of glial and glioma cells. Using novel technol-
ogy, we investigated the metabolic fates of glucose in GBM cells
that have not been determined in vivo before. At present, our in
vivo analysis is limited to one invasive orthotopic glioma model
and further studies on other invasive models are warranted.
Infiltrating glioma cells preserve mitochondrial glucose
oxidation similarly to glial cells
GBM is known for the elevated rates of glucose consumption
in the regions close to the tumor core. This phenomenon,
often observed in patients with 18FDG PET, is thought to
reﬂect the Warburg effect in tumor cells that promotes
anaerobic glucose metabolism and Lac production, simulta-
neously decreasing the mitochondrial functionality. Lac con-
centration can be detected non-invasively by 1H MRS,
however, correlations with 18FDG measurements in humans
indicated that the Lac signal intensity is not always associated
with hypermetabolic regions,23 but may be increased in
necrosis possibly due to reduced clearance.24 Therefore,
increased glucose uptake would only be effectively detected
by 18FDG PET. In our model, SUV maps reﬂecting 18FDG
uptake in injected mice did not show substantially increased
values compared to cerebral metabolism. On the contrary,
extended hypointense areas were observed by visual inspec-
tion (Fig. 1a), possibly reﬂecting a reduced glucose uptake in
“suffering” cells. This apparent contradiction with the classi-
cal model of glioma metabolism is probably explained by the
absence of a central necrosis in the current model used. A shift
toward anaerobic metabolism is in fact typical of tumor cells
in hypoxic and nutrient-restricted conditions25 and has been
recently associated with increased migration in GBM and nor-
mal brain cells,26 with hypoxia representing the trigger for
migration. In contrast, glioma cells inﬁltrating the normal
brain have access to normal nutrient concentrations and oxy-
gen tension and, therefore, may not require extensive meta-
bolic reprograming to support tumor development, in
agreement with the proposition that upregulation of glycolysis
maybe associated with the angiogenic switch.27 This would be
compatible (i) with the relatively low levels of Lac observed in
our invasive model that were comparable to non-tumor bear-
ing mice (Figs. 1b and 2a), (ii) a minor role of Lac in the PCA
during tumor evolution and at late time points (Figs. 2a and
3a) and (iii) the lack of a correlation of Lac with the ratio
human/mouse cells (Fig. 4d). Consequently, brain tumors not
affected by the Warburg effect would not be detected by PET
in patients, both due to low cell density and superposition
with hypermetabolic cells. It is of note, increased Lac concen-
trations are detected in other orthotopic glioma xenograft
mouse models yielding compact tumors, and are more promi-
nent when displaying gadolinium uptake and necrosis – indi-
cating presence of hypoxia – as we reported previously.7
The absence of a necrotic core is commonly observed in
xenograft models derived from glioma stem-like cells.1,28
Necrotic regions are often associated with reduced concentra-
tions of Glu and Gln due to neuronal loss and reduced glu-
cose oxidation. However, the direct assessment of Glu and
Gln concentration in vivo is quite challenging. Although their
separate estimation in humans is feasible at 3 T3, this
might be further complicated by the spectral superposition
with macromolecules, lipid signals in high grade gliomas and
increased tissue inhomogeneity. Under these conditions, the
viable tumor cells and the invasive front are even more difﬁ-
cult to assess with in vivo 13C MRS due to reduced sensitivity
and spatial resolution. This has limited in vivo 13C MRS
studies for the detection and modeling of Lac turnover, the
most prominent signal in glycolytic tumors, such as C6 gli-
oma bearing rats.29 In contrast, LN-2669GS cells yield a gli-
oma model that affects large portions of the mouse brain
homogeneously, enabling for the ﬁrst time the detection of
13C MR spectra in vivo during glioma invasion. 13C detection
at 14.1 T allowed the accurate measurement of cell-speciﬁc
metabolic ﬂuxes in vivo in volumes as small as 60 mL, with
the separate detection of C4, C3, C2 resonances of Glu and
Gln labeled by [1,6-13C]glucose (Fig. 5).
The Glu pool determined by MRS was ascribed to neu-
rons according to the modeling scheme, as further supported
by the high correlation over time of Glu with NAA, a known
neuronal marker (Fig. 2b). Since glioma cells represented a
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signiﬁcant fraction of the cells included in the volume of
interest (63–65%), the increased size of the Gln pool in
injected mice suggests that GBM cells might be metabolically
similar to glial cells. In previous ex vivo studies,8 it was
shown that GBM cells have an oxidative activity, can also
metabolize other substrates than glucose and supply anaple-
rosis. These metabolic functions are similar to the ones of
the glial compartment used in 13C two-compartment model-
ing.16 Therefore, the GBM cells were included in the same
kinetic compartment for the analysis. Thus, Gln was entirely
attributed to the glial-GBM compartment. In the analysis of
the temporal evolution of metabolite concentrations mea-
sured by 1H MRS, Gln mostly aligned with the primary axis
in anticorrelation with NAA, Glu and GABA (Fig. 3a).
Figure 6. Metabolic modeling of in vivo 13C MRS in glioma bearing mice. (a) Two-compartmental model of glucose metabolism in the brain of
glioma bearing mice. Glioma cells are assumed to constitute a homogeneous pool with glial cells. The carbon skeleton of labeled molecules is
shown and the labeled carbon position is colored (pink) and indicated as Ci (i51,2, . . .,6). [1,6-
13C]glucose is assumed to enter brain cells
(neurons, glia and glioma) and undergo glycolysis leading to labeling of [3–13C]pyruvate and [3–13C]lactate. The lactate pool, common to both
compartments, contributes to non-oxidative pathways and is diluted from blood-born unlabeled lactate. [3–13C]Pyruvate enters the mitochon-
dria and leads to labeling of [4–13C]glutamate in both compartments from the first turn of the TCA cycle (dark pink). Pyruvate carboxylase (PC)
activity is considered to be specific for glia and glioma cells as glutamine synthetase (GS) converts [4–13C]glutamate into [4–13C]glutamine. PC
activity generates efflux of labeled glutamine to the extracellular compartment due to mass-balance constraints. [4–13C]Glutamine is transferred
to the neuronal compartment through the glutamate/glutamine cycle involved in excitatory neurotransmission, converted back to [4–13C]gluta-
mate which is then released into the extracellular space during synaptic transmission to enter again the GBM-glial compartment. Further turns
of the TCA cycle will similarly label [3–13C] and [2–13C]glutamate and glutamine. (b) Metabolic fluxes quantified from compartmental modeling
in healthy brains (n56) and tumor bearing brains (n53) under infusion of [1,6-13C]glucose (Glc). Errors express SD derived from Monte Carlo
simulations with a set of N5300 artificial set of curves for Glu, Gln C4, C3 and C2. Cerebral metabolic rate of glucose (CMRglc(ox)) is calculated
as (VnTCA1V
g
TCA1VPC)/2. Significant correlations are indicated (*p<0.05, ***p<0.001, Student’s t-test with Bonferroni’s correction). [Color fig-
ure can be viewed at wileyonlinelibrary.com]
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Therefore, Gln concentrations increased with the concomi-
tant decrease in NAA, paralleling an augmented presence of
GBM cells relative to neurons. Previously published studies
in different orthotopic mouse models have been reporting
discordant values for Gln variations in GBM,30 reporting
either unchanged levels6 or decreasing Gln concentrations,7
possibly reﬂecting different GBM cell densities or metabolic
heterogeneities between the different models. The presence of
a large Gln pool compared to normal brain, and higher 13C-
labeling in Gln signals in presence of signiﬁcant glucose oxi-
dation have also been reported in ex vivo 13C MRS studies
on a mouse model obtained from glioma spheres,8 similar to
our ﬁndings (Supporting Information Fig. S3 and Fig. 6).
Our in vivo observations also support the conclusion that gli-
oma cells are able to metabolize glucose in the mitochondria
for the synthesis of Glu and Gln. Moreover, glioma cells pre-
serve signiﬁcant anaplerotic activity through pyruvate carbox-
ylation (VPC) similarly to control conditions (Fig. 6b).
In summary, our longitudinal 1H MRS data described the
inﬁltrative growth of human GBM cells and their metabolic
characteristics, which have not yet been explored in vivo. The
trend of a temporal shift of the changes in the metabolic pro-
ﬁles of WIF1 expressing xenografts to later time points, is in
agreement with our previous observations of decreased
migratory potential and prolonged survival mediated by
attenuation of the WNT-pathway.10 The metabolic proﬁles
shown at late stage differ from human high grade glioma by
their relatively low levels of lactate, myo-inositol and glycine.
A striking observation was the presence of a substantial oxi-
dative glucose metabolism in glioma cells, in absence of
increased glycolytic rates, as revealed by 13C MRS and 18FDG
PET. Therefore, we conclude that citric acid cycle activity,
anaplerosis and synthesis of glucose-derived glutamine may
be active pathways during tumor inﬁltration in vivo, which
reveals an unexpected metabolic difference between glioma
cells when compared to highly glycolytic cells, which have
been mostly associated with necrosis and hypoxia in previous
studies. This metabolic difference certainly needs to be taken
into account when devising novel treatment strategies target-
ing the invasive front.
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